BACKGROUND: Crohn's disease (CD) is a chronic inflammatory intestinal disorder associated with intestinal dysbiosis. Diet modulates the intestinal microbiome and therefore has a therapeutic potential. The aim of this study is to determine the potential efficacy of three versions of the specific carbohydrate diet (SCD) in active Crohn's Disease. METHODS:18 patients with mild/moderate CD (PCDAI 15-45) aged 7 to 18 years were enrolled. Patients were randomized to either SCD, modified SCD(MSCD) or whole foods (WF) diet. Patients were evaluated at baseline, 2, 4, 8 and 12 weeks. PCDAI, inflammatory labs and multi-omics evaluations were assessed. RESULTS:Mean age was 14.3 ± 2.9 years. At week 12, all participants (n = 10) who completed the study achieved clinical remission. The C-reactive protein decreased from 1.3 ± 0.7 at enrollment to 0.9 ± 0.5 at 12 weeks in the SCD group. In the MSCD group, the CRP decreased from 1.6 ± 1.1 at enrollment to 0.7 ± 0.1 at 12 weeks. In the WF group, the CRP decreased from 3.9 ± 4.3 at enrollment to 1.6 ± 1.3 at 12 weeks. In addition, the microbiome composition shifted in all patients across the study period. While the nature of the changes was largely patient specific, the predicted metabolic mode of the organisms increasing and decreasing in activity was consistent across patients. CONCLUSIONS: This study emphasizes the impact of diet in CD. Each diet had a positive effect on symptoms and inflammatory burden; the more exclusionary diets were associated with a better resolution of inflammation.
RCT Entities:
BACKGROUND:Crohn's disease (CD) is a chronic inflammatory intestinal disorder associated with intestinal dysbiosis. Diet modulates the intestinal microbiome and therefore has a therapeutic potential. The aim of this study is to determine the potential efficacy of three versions of the specific carbohydrate diet (SCD) in active Crohn's Disease. METHODS: 18 patients with mild/moderate CD (PCDAI 15-45) aged 7 to 18 years were enrolled. Patients were randomized to either SCD, modified SCD(MSCD) or whole foods (WF) diet. Patients were evaluated at baseline, 2, 4, 8 and 12 weeks. PCDAI, inflammatory labs and multi-omics evaluations were assessed. RESULTS: Mean age was 14.3 ± 2.9 years. At week 12, all participants (n = 10) who completed the study achieved clinical remission. The C-reactive protein decreased from 1.3 ± 0.7 at enrollment to 0.9 ± 0.5 at 12 weeks in the SCD group. In the MSCD group, the CRP decreased from 1.6 ± 1.1 at enrollment to 0.7 ± 0.1 at 12 weeks. In the WF group, the CRP decreased from 3.9 ± 4.3 at enrollment to 1.6 ± 1.3 at 12 weeks. In addition, the microbiome composition shifted in all patients across the study period. While the nature of the changes was largely patient specific, the predicted metabolic mode of the organisms increasing and decreasing in activity was consistent across patients. CONCLUSIONS: This study emphasizes the impact of diet in CD. Each diet had a positive effect on symptoms and inflammatory burden; the more exclusionary diets were associated with a better resolution of inflammation.
Authors: Jeffrey Hyams; James Markowitz; Anthony Otley; Joel Rosh; David Mack; Athos Bousvaros; Subra Kugathasan; M Pfefferkorn; Vasundhara Tolia; Jonathan Evans; William Treem; Robert Wyllie; Robert Rothbaum; J del Rosario; Aubrey Katz; Adam Mezoff; M Oliva-Hemker; Trudy Lerer; Anne Griffiths Journal: J Pediatr Gastroenterol Nutr Date: 2005-10 Impact factor: 2.839
Authors: Arie Levine; Eytan Wine; Amit Assa; Rotem Sigall Boneh; Ron Shaoul; Michal Kori; Shlomi Cohen; Sarit Peleg; Hussein Shamaly; Avi On; Peri Millman; Lee Abramas; Tomer Ziv-Baran; Shannan Grant; Guila Abitbol; Katherine A Dunn; Joseph P Bielawski; Johan Van Limbergen Journal: Gastroenterology Date: 2019-06-04 Impact factor: 22.682
Authors: Stephen M Vindigni; Timothy L Zisman; David L Suskind; Christopher J Damman Journal: Therap Adv Gastroenterol Date: 2016-04-19 Impact factor: 4.409
Authors: Ben P Willing; Johan Dicksved; Jonas Halfvarson; Anders F Andersson; Marianna Lucio; Zongli Zheng; Gunnar Järnerot; Curt Tysk; Janet K Jansson; Lars Engstrand Journal: Gastroenterology Date: 2010-10-08 Impact factor: 22.682
Authors: Rachel N Carmody; Georg K Gerber; Jesus M Luevano; Daniel M Gatti; Lisa Somes; Karen L Svenson; Peter J Turnbaugh Journal: Cell Host Microbe Date: 2014-12-18 Impact factor: 21.023
Authors: Jonas Halfvarson; Colin J Brislawn; Regina Lamendella; Yoshiki Vázquez-Baeza; William A Walters; Lisa M Bramer; Mauro D'Amato; Ferdinando Bonfiglio; Daniel McDonald; Antonio Gonzalez; Erin E McClure; Mitchell F Dunklebarger; Rob Knight; Janet K Jansson Journal: Nat Microbiol Date: 2017-02-13 Impact factor: 17.745
Authors: Arie Levine; Sibylle Koletzko; Dan Turner; Johanna C Escher; Salvatore Cucchiara; Lissy de Ridder; Kaija-Leena Kolho; Gabor Veres; Richard K Russell; Anders Paerregaard; Stephan Buderus; Mary-Louise C Greer; Jorge A Dias; Gigi Veereman-Wauters; Paolo Lionetti; Malgorzata Sladek; Javier Martin de Carpi; Annamaria Staiano; Frank M Ruemmele; David C Wilson Journal: J Pediatr Gastroenterol Nutr Date: 2014-06 Impact factor: 3.288
Authors: James D Lewis; Robert S Sandler; Carol Brotherton; Colleen Brensinger; Hongzhe Li; Michael D Kappelman; Scott G Daniel; Kyle Bittinger; Lindsey Albenberg; John F Valentine; John S Hanson; David L Suskind; Andrea Meyer; Charlene W Compher; Meenakshi Bewtra; Akriti Saxena; Angela Dobes; Benjamin L Cohen; Ann D Flynn; Monika Fischer; Sumona Saha; Arun Swaminath; Bruce Yacyshyn; Ellen Scherl; Sara Horst; Jeffrey R Curtis; Kimberly Braly; Lisa Nessel; Maureen McCauley; Liam McKeever; Hans Herfarth Journal: Gastroenterology Date: 2021-05-27 Impact factor: 33.883